MLTX vs. PCVX, SRPT, QGEN, ASND, ROIV, RVMD, LEGN, BBIO, AXSM, and BPMC
Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry.
MoonLake Immunotherapeutics vs.
MoonLake Immunotherapeutics (NASDAQ:MLTX) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership.
MoonLake Immunotherapeutics has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.
MoonLake Immunotherapeutics' return on equity of -15.54% beat Vaxcyte's return on equity.
In the previous week, Vaxcyte had 3 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 7 mentions for Vaxcyte and 4 mentions for MoonLake Immunotherapeutics. Vaxcyte's average media sentiment score of 1.08 beat MoonLake Immunotherapeutics' score of 0.86 indicating that Vaxcyte is being referred to more favorably in the news media.
MoonLake Immunotherapeutics received 18 more outperform votes than Vaxcyte when rated by MarketBeat users. Likewise, 81.01% of users gave MoonLake Immunotherapeutics an outperform vote while only 75.41% of users gave Vaxcyte an outperform vote.
MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.
MoonLake Immunotherapeutics currently has a consensus target price of $85.50, indicating a potential upside of 102.22%. Vaxcyte has a consensus target price of $127.71, indicating a potential upside of 60.16%. Given MoonLake Immunotherapeutics' higher possible upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Vaxcyte.
93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 3.1% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
MoonLake Immunotherapeutics beats Vaxcyte on 10 of the 15 factors compared between the two stocks.
Get MoonLake Immunotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MoonLake Immunotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MLTX) was last updated on 2/21/2025 by MarketBeat.com Staff
